By Anthony O. Goriainoff

GSK said Japan has accepted for review a supplementary new drug application for its Nucala (mepolizumab) product for the treatment of adults with chronic rhinosinusitis with nasal polyps.

The U.K. pharmaceutical giant said Friday that if approved, mepolizumab would be the first anti-interleukin-5--a pro-inflammatory protein--for adult patients in Japan.

GSK said this would be Nucala's third indication in Japan for an interleukin-5 mediated condition.

The company said mepolizumab--an antibody targeting interleukin-5--is already approved in Japan as a treatment for bronchial asthma in children above the age of six, as well as adults with refractory asthma whose symptoms are inadequately controlled with standard treatments.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

September 01, 2023 02:32 ET (06:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos GSK.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos GSK.